Feasibility Study on Human Therapeutic Proteins

The companies are Debiopharm S.A. (Lausanne, Switzerland) and Biolex, Inc. (Pittsboro, N.C., USA).

Debiopharm has recombinant therapeutic proteins in its development portfolio that the company believes could be advanced through the use of Biolex's protein expression system, called Lemna. This system combines the natural characteristics of Lemna, a green aquatic plant, with advanced genetic engineering and protein recovery methods.
Debiopharm has a successful track record of developing and bringing to market new drugs for cancer, but believes Lemna could provide not only speed but also better levels of pathogen safety for therapeutic proteins.

"We see this collaboration as an important first step in what we believe will be an expansive alliance to jointly develop innovative therapeutic protein products,” said Jan Turek, president and CEO of Biolex.